BACKGROUND: Pulmonary arterial hypertension (PAH) is a common complication among patients with congenital heart disease (CHD). Despite advances in PAH treatment, evidence for the benefits of PAH therapies in CHD-PAH is limited. OBJECTIVES: This analysis aimed to evaluate outcomes in patients with repaired PAH-CHD receiving an approved PAH drug. METHODS: This was a pooled analysis including CHD-PAH patients whose CHD was repaired ≥1 year prior from 3 randomized, placebo-controlled, event-driven studies: GRIPHON (NCT01106014), SERAPHIN (NCT00660179), and COMPASS-2 (NCT00303459). The primary endpoint was time to first confirmed morbidity/mortality (M/M) event. HRs with 95% CIs were determined with random effects models. RESULTS: The analysis included 1,982 patients with PAH, 177 (8.9%) with CHD-PAH. In the overall PAH cohort, the mean age was 48 and 49 years in treatment and placebo groups; 80% and 77% were female. In the CHD-PAH cohort, the mean age was 41 and 39 years; 70% and 66% were female. Overall, ≥98% in each group were World Health Organization functional class II and III at baseline. There was a significant reduction in risk of M/M events vs placebo in the overall PAH and CHD-PAH cohorts: 37% reduction in the overall PAH cohort (HR: 0.63; 95% CI: 0.52-0.77) and 50% reduction in the CHD-PAH population (HR: 0.50; 95% CI: 0.26-0.94). CONCLUSIONS: Treatment with approved PAH drugs provided a similar reduction in M/M risk in patients with repaired CHD-PAH when compared with the overall PAH population. This pooled analysis provides important evidence to guide medical management in this patient population.

Ahmanson UCLA Adult Congenital Heart Disease Center University of California Los Angeles California USA

Cardiology and Center of Cardiovascular Medicine Medical University of Vienna Vienna Austria

CARE Hospitals Hyderabad India

Centre of Postgraduate Medical Education European Health Centre Otwock Poland

Charles University and General University Hospital Prague Czech Republic

David Geffen School of Medicine at University of California Los Angeles Los Angeles California USA

Duke University Health System Durham North Carolina USA

Hannover Medical School Hannover Germany; German Center of Lung Research Hannover Germany

Ignacio Chavez National Heart Institute Mexico Mexico

Johnson and Johnson Titusville New Jersey USA

London Health Sciences Centre Schulich School of Medicine and Dentistry Western University London Ontario Canada

Mater Misericordiae University Hospital Dublin Ireland

Université Paris Saclay APHP Hôpital Bicêtre Le Kremlin Bicêtre France

University of Michigan Health System Ann Arbor Michigan USA

University of Texas Southwestern Medical Center Dallas Texas USA

Zobrazit více v PubMed

Engelfriet P.M., Duffels M.G., Möller T., et al. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease. Heart. 2007;93(6):682–687. doi: 10.1136/hrt.2006.098848. PubMed DOI PMC

Humbert M., Kovacs G., Hoeper M.M., et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61(1) doi: 10.1183/13993003.00879-2022. PubMed DOI

Lau E.M.T., Giannoulatou E., Celermajer D.S., Humbert M. Epidemiology and treatment of pulmonary arterial hypertension. Nat Rev Cardiol. 2017;14(10):603–614. doi: 10.1038/nrcardio.2017.84. PubMed DOI

Lowe B.S., Therrien J., Ionescu-Ittu R., Pilote L., Martucci G., Marelli A.J. Diagnosis of pulmonary hypertension in the congenital heart disease adult population impact on outcomes. J Am Coll Cardiol. 2011;58(5):538–546. doi: 10.1016/j.jacc.2011.03.033. PubMed DOI

Chang K.Y., Duval S., Badesch D.B., et al. Mortality in pulmonary arterial hypertension in the modern era: early insights from the Pulmonary Hypertension Association Registry. J Am Heart Assoc. 2022;11(9):e024969. doi: 10.1161/jaha.121.024969. PubMed DOI PMC

Hoeper M.M., Pausch C., Grünig E., et al. Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry. Eur Respir J. 2022;59(6) doi: 10.1183/13993003.02024-2021. PubMed DOI PMC

Muller A., Escribano-Subias P., Fernandes C.C., et al. Real-world management of patients with pulmonary arterial hypertension: insights from EXPOSURE. Adv Ther. 2024;41(3):1103–1119. doi: 10.1007/s12325-023-02730-8. PubMed DOI PMC

Quan R., Zhang G., Yu Z., et al. Characteristics, goal-oriented treatments and survival of pulmonary arterial hypertension in China: insights from a national multicentre prospective registry. Respirology. 2022;27(7):517–528. doi: 10.1111/resp.14247. PubMed DOI

Liu A., Diller G.P., Moons P., Daniels C.J., Jenkins K.J., Marelli A. Changing epidemiology of congenital heart disease: effect on outcomes and quality of care in adults. Nat Rev Cardiol. 2023;20(2):126–137. doi: 10.1038/s41569-022-00749-y. PubMed DOI

Frogoudaki A.A., Gatzoulis M.A. Pulmonary arterial hypertension in congenital heart disease. Continuing Cardiology Education. 2018;4(1):23–33. doi: 10.1002/cce2.74. DOI

Farber H.W., Miller D.P., Poms A.D., et al. Five-year outcomes of patients enrolled in the REVEAL Registry. Chest. 2015;148(4):1043–1054. doi: 10.1378/chest.15-0300. PubMed DOI

Manes A., Palazzini M., Leci E., Bacchi Reggiani M.L., Branzi A., Galiè N. Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. Eur Heart J. 2014;35(11):716–724. doi: 10.1093/eurheartj/eht072. PubMed DOI

Alonso-Gonzalez R., Lopez-Guarch C.J., Subirana-Domenech M.T., et al. Pulmonary hypertension and congenital heart disease: an insight from the REHAP National Registry. Int J Cardiol. 2015;184:717–723. doi: 10.1016/j.ijcard.2015.02.031. PubMed DOI

McLaughlin V., Channick R.N., Ghofrani H.A., et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J. 2015;46(2):405–413. doi: 10.1183/13993003.02044-2014. PubMed DOI

Pulido T., Adzerikho I., Channick R.N., et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809–818. doi: 10.1056/NEJMoa1213917. PubMed DOI

Sitbon O., Channick R., Chin K.M., et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522–2533. doi: 10.1056/NEJMoa1503184. PubMed DOI

Beghetti M., Channick R.N., Chin K.M., et al. Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. Eur J Heart Fail. 2019;21(3):352–359. doi: 10.1002/ejhf.1375. PubMed DOI PMC

Legha A., Riley R.D., Ensor J., Snell K.I.E., Morris T.P., Burke D.L. Individual participant data meta-analysis of continuous outcomes: a comparison of approaches for specifying and estimating one-stage models. Stat Med. 2018;37(29):4404–4420. doi: 10.1002/sim.7930. PubMed DOI PMC

Riley R.D., Lambert P.C., Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ. 2010;340:c221. doi: 10.1136/bmj.c221. PubMed DOI

Channick R., Delcroix M., Ghofrani H., et al. Effect of macitentan on hospitalizations: results from the SERAPHIN trial. J Am Coll Cardiol HF. 2015;3(1):1–8. doi: 10.1016/j.jchf.2014.07.013. PubMed DOI